VIA
ORIC icon

Virtus Investment Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

Virtus Investment Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$368K Buy
29,069
+708
+2% +$8.04K 0.1% 252
2025
Q4 		$232K Buy
28,361
+16,594
+141% +$191K 0.06% 354
2025
Q3 		$141K Buy
11,767
+2,043
+21% +$21.5K 0.04% 386
2025
Q2 		$98.7K Sell
9,724
-9,749
-50% -$65.4K 0.03% 338
2025
Q1 		$109K Buy
+19,473
New +$170K 0.03% 408

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Virtus Investment Advisers's ORIC Position: Q1 2026 in Review

Virtus Investment Advisers increased its Oric Pharmaceuticals (ORIC) stake by 2.5% in Q1 2026, buying an estimated $8.04K and bringing the position to 29,069 shares worth $368K. The position accounts for 0.1% of the portfolio, ranked #252.

Virtus Investment Advisers first reported a position in ORIC in Q1 2025 and has held it in 5 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Virtus Investment Advisers held 29,069 shares of Oric Pharmaceuticals worth $368K as of Q1 2026.
  • Virtus Investment Advisers bought 708 Oric Pharmaceuticals shares in Q1 2026, an estimated $8.04K.
  • Oric Pharmaceuticals made up 0.1% of Virtus Investment Advisers's portfolio in Q1 2026, its #252 holding.
  • Virtus Investment Advisers first reported a position in Oric Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.